Is SCLN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

624 people get SCLN articles and Market Currents by email alert.

Get email alerts on SCLN »

HEADLINES:

China Biotech In Review: SciClone Pharma In-Licenses China Rights To Heart Failure Drug
ChinaBio Today • Sun, May 19
SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China Market

Marketwire (May 16, 2013)
SciClone Reports Anticipated Financial Results for the First Quarter 2013

Marketwire (May 16, 2013)
Income Idea: 2 Undervalued Drug Makers With Rising Gross Profit Margins
Kapitall • Fri, May 10 • 1 Comment
SciClone Appoints PricewaterhouseCoopers LLP as Its Independent Registered Public Accounting Firm

Marketwire (Apr 8, 2013)
SciClone Pharmaceuticals' Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Apr 1
SciClone Reports 2012 Financial Results and 2013 Outlook

Marketwire (Apr 1, 2013)
SciClone Pharmaceuticals to Report 2012 Financial Results and 2013 Outlook on April 1st

Marketwire (Apr 1, 2013)
SciClone Appoints Hong Zhao as Chief Executive Officer, China Operations

Marketwire (Mar 22, 2013)
SciClone Provides Update on the Timing of Filing Its 2012 Annual Report on Form 10-K

Marketwire (Mar 14, 2013)
SciClone's Credibility Takes Another Hit; So Will The Stock
PropThink • Mon, Feb 25 • 1 Comment
SciClone to Restate Financial Statements for 2012 and 2011 Periods

Marketwire (Feb 22, 2013)
5 Medical Stock Losers From Last Week With High Short Ratios
Heisenberg Principle • Mon, Feb 11
SciClone to Present at BIO CEO & Investor Conference on February 12th

Marketwire (Feb 4, 2013)
SciClone Pharmaceuticals: A Promising Biotech Stock
Brett Wilson • Mon, Feb 4 • 5 Comments
SciClone Announces Product Promotion Agreement Renewal With Key Industry Parnter Sanofi in China

Marketwire (Jan 30, 2013)
SciClone Announces Appointment of Simon Li to Its Board of Directors

Marketwire (Jan 14, 2013)
SCLN Guidance Offers Confidence, Stock Is Cheap, And Breaking Out Technically
PropThink • Fri, Jan 11
SciClone Provides Initial 2013 Financial Guidance

Marketwire (Jan 7, 2013)
A Dozen Rapidly Growing Stocks Getting No Respect
Alan Brochstein • Sun, Dec 30, 2012 • 20 Comments

To learn more about Seeking Alpha Pro, click here.

SciClone's Credibility Takes Another Hit; So Will The Stock
PropThink • Mon, Feb 25 • 1 Comment
SciClone Pharmaceuticals: A Promising Biotech Stock
Brett Wilson • Mon, Feb 4 • 5 Comments
SCLN Guidance Offers Confidence, Stock Is Cheap, And Breaking Out Technically
PropThink • Fri, Jan 11
SciClone On Solid Ground; Stock Is Cheap, And Large Investors Are Buying
PropThink • Thu, Nov 29, 2012
SciClone Pharmaceuticals: Promising Biotech With China Exposure
David Zanoni • Tue, Sep 18, 2012
Rapid Chinese Growth Is Powering This Cheap, Cash Rich $5 Pharma Stock
Bret Jensen • Wed, Aug 8, 2012 • 8 Comments
Despite Legal And China Concerns, Prospects Are Strong For SciClone Pharmaceuticals
LifeSci Advisors • Wed, Aug 1, 2012 • 4 Comments
SciClone's Strategic Partner Selling Out; SEC, DOJ And Competitors Closing In
The GeoTeam • Wed, Jul 11, 2012 • 11 Comments
SciClone Pharmaceuticals: Not Ready For Prime Time
Douglas W. House • Fri, Jun 15, 2012 • 2 Comments
SciClone Pharmaceuticals Is Dramatically Increasing Profits
Roy Manning III • Mon, Apr 9, 2012 • 1 Comment
SciClone: Novamed Acquisition Helps, But Questions Remain
General Biologic • Fri, May 20, 2011

China Biotech In Review: SciClone Pharma In-Licenses China Rights To Heart Failure Drug
ChinaBio Today • Sun, May 19
Income Idea: 2 Undervalued Drug Makers With Rising Gross Profit Margins
Kapitall • Fri, May 10 • 1 Comment
5 Medical Stock Losers From Last Week With High Short Ratios
Heisenberg Principle • Mon, Feb 11
A Dozen Rapidly Growing Stocks Getting No Respect
Alan Brochstein • Sun, Dec 30, 2012 • 20 Comments
3 Low PEG Stocks With Positive Momentum
Arie Goren • Sat, Sep 22, 2012 • 2 Comments
9 Undervalued Stocks Being Bought Aggressively By Hedge Funds
Kapitall • Sat, Sep 22, 2012 • 2 Comments
3 Stocks Upgraded On September 18 To Consider
Jorge Aura • Thu, Sep 20, 2012
4 Low-Debt Healthcare Stocks With Hefty Earnings Trends
ZetaKap • Tue, Sep 4, 2012
7 Profitable Small-Cap Healthcare Stocks With Cash On Hand
ZetaKap • Thu, Aug 2, 2012 • 1 Comment
7 Small Cap Healthcare Stocks Bringing In Cash And Maintaining Great Liquidity
ZetaKap • Mon, Jul 30, 2012
2 Biotech Lottery Tickets, Each For Less Than $2
Bret Jensen • Tue, Jul 10, 2012 • 15 Comments
3 Promising Pharma Companies Projected To Grow 5 Times Faster Than The S&P 500
Matt Schilling • Fri, Jul 6, 2012 • 21 Comments
4 Stocks Hitting New Highs In A Weak Tape
Joshua Hayes • Wed, Jun 13, 2012 • 2 Comments
Noteworthy Insider Buys And Sells In The Healthcare Sector
GuruFundPicks • Fri, Jun 8, 2012
14 Outperforming Small Caps Undervalued By EPS Trends
Kapitall • Wed, May 23, 2012
Analyzing Noteworthy Insider Trades Last Week In Regeneron, Covidien, And Other Healthcare Stocks
GuruFundPicks • Mon, May 7, 2012
2 Biotech Stocks That Could Jump On Hepatitis C Breakthroughs
Ry Frank • Fri, Apr 27, 2012
8 Highly Liquid Healthcare Stocks Undervalued By EPS Trends
Kapitall • Wed, Apr 18, 2012
Top Small-Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 6 Comments
Power-One, RRsat Could Go Much Higher
Bret Jensen • Thu, Mar 15, 2012 • 6 Comments

SciClone Pharmaceuticals' Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Apr 1
SciClone Pharmaceuticals Management Presents at Lazard Capital Markets Healthcare Conference (Transcript)
Thu, Nov 15, 2012
SciClone Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012
SciClone Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012
SciClone Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Thu, Mar 13, 2008

SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China Market

Marketwire (May 16, 2013)
SciClone Reports Anticipated Financial Results for the First Quarter 2013

Marketwire (May 16, 2013)
SciClone Appoints PricewaterhouseCoopers LLP as Its Independent Registered Public Accounting Firm

Marketwire (Apr 8, 2013)
SciClone Reports 2012 Financial Results and 2013 Outlook

Marketwire (Apr 1, 2013)
SciClone Pharmaceuticals to Report 2012 Financial Results and 2013 Outlook on April 1st

Marketwire (Apr 1, 2013)
SciClone Appoints Hong Zhao as Chief Executive Officer, China Operations

Marketwire (Mar 22, 2013)
SciClone Provides Update on the Timing of Filing Its 2012 Annual Report on Form 10-K

Marketwire (Mar 14, 2013)
SciClone to Restate Financial Statements for 2012 and 2011 Periods

Marketwire (Feb 22, 2013)
SciClone to Present at BIO CEO & Investor Conference on February 12th

Marketwire (Feb 4, 2013)
SciClone Announces Product Promotion Agreement Renewal With Key Industry Parnter Sanofi in China

Marketwire (Jan 30, 2013)
SciClone Announces Appointment of Simon Li to Its Board of Directors

Marketwire (Jan 14, 2013)
SciClone Provides Initial 2013 Financial Guidance

Marketwire (Jan 7, 2013)
SciClone to Present at Oppenheimer 23rd Annual Healthcare Conference on December 13th

Marketwire (Dec 5, 2012)
SciClone Announces New ZADAXIN(R) Anti-Counterfeiting Label Wins Major Industry Award

Marketwire (Dec 4, 2012)
SciClone to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th

Marketwire (Nov 12, 2012)
SciClone Reports Financial Results for the Third Quarter 2012 and 2012 Outlook

Marketwire (Nov 9, 2012)
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2012 and 2012 Outlook on November 9th

Marketwire (Nov 8, 2012)
SciClone Announces China Government-Mandated ZADAXIN(R) Price Reduction; Anticipates Minimal Impact on Revenue and Margins

Marketwire (Sep 18, 2012)
SciClone Announces Management Transitions in China Operations

Marketwire (Sep 10, 2012)
SciClone Pharmaceuticals to Present at Investor Conferences in September 2012

Marketwire (Aug 28, 2012)

SCLN vs. ETF Alternatives

Company Description

Currently, there's no company description for SCLN.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 4:20 PM SciClone Pharmaceuticals (SCLN) says it's entered into an agreement with Zensun Science & Technology granting SCLN a license and exclusive marketing and distribution rights to sell Neucardin, a treatment for intermediate to advanced chronic heart failure, in China, Hong Kong and Macau. Comment! [Healthcare, On the Move, Global & FX]
Monday, April 1, 4:19 PM SciClone (SCLN): Q4 EPS of $0.03 misses by $0.09. Revenue of $33.4M misses by $1.9M. Shares -2.6% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Friday, March 22, 8:15 AM China-focused SciClone Pharmaceuticals (SCLN -0.9%) has appointed former Simcere Pharmaceutical Group Executive VP Hong Zhao as its CEO of operations in China. SciClone, which markets its flagship drug ZADAXIN in over 30 countries, said Mr. Zhao has a proven track record of delivering "strong top and bottom-line performance." Comment! [Healthcare, Global & FX]
Friday, February 22, 5:45 PM After-hours top gainers, as of 5:15 p.m.: EXEL +3%. DSLV +3%. BLT +2%. CY +2%. CZR +2%.
After-hours top losers: WETF -8%. SCLN -5%. MMSI -4%. ANF -3%. CHTR -3%. Comment! [On the Move]
Friday, February 22, 4:29 PM SciClone Pharmaceuticals (SCLN) says it will be restating financial statements for fiscal Q1, Q2, Q3 of 2011 as well as Q2 and Q3 in 2012 to account for accounting errors within its NovaMed subsidiary in China. The restatement primarily relates to accounting errors over the timing of Pfizer product revenue recognition and the recognition of product return reserves for its Aggrastat anticoagulant drug. SCLN acquired NovaMed in April 2011. Shares -6% AH. 1 Comment [Healthcare, Earnings]
Monday, January 7, 2:52 PM SciClone Pharmaceuticals (SCLN +0.5%) updates its 2013 outlook, now expecting an initial EPS of $0.66 - $0.72 per share on revenues of between $150M - $155M. Analysts are looking for the company to earn $0.65 on revenue of around $152M. 1 Comment [Healthcare]
Monday, November 12, 2012, 5:45 PM After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD +8.1%.
After-hours top losers: INFI -8.6%. SCLN -5.5%. EVER -4.4%. GME -4.1%. MWE -3.7%. Comment! [On the Move]
Friday, November 9, 2012, 12:45 PM Midday top 10 gainers: HWG +66%. KIPS +41%. KYAK +27%. ZIP +25%. SQNM +22%. UBNT +19%. DGIT +17%. SQI +16%. CYTX +16%. ISIS +15%. Midday top 10 Losers: GRPN -27%. DTSI -26%. SCLN -24%. IDN -23%. RNDY -21%. III -17%. ADEP -17%. OSG -17%. STRA -16%. PTIX -15%. Comment!
Friday, November 9, 2012, 6:21 AM SciClone Pharmaceuticals (SCLN): Q3 EPS of $0.20 misses by $0.01. Revenue of $40.6M (+8.8% Y/Y). (PR) Comment! [Earnings, Healthcare]
Thursday, August 9, 2012, 2:31 PM SciClone Pharmaceuticals (SCLN +16.8%) are soaring after its Q2 bottom line topped Street estimates late yesterday. Total revenue jumped 22% Y/Y, helped by a 27% increase in sales of its drug Zadaxin, plus revenue growth from its primary care and oncology businesses in China and positive synergies from its recent takeover of NovaMed Pharmaceuticals. Comment! [Healthcare, Earnings, On the Move]
Wednesday, August 8, 2012, 4:06 PM SciClone Pharmaceuticals (SCLN): Q2 EPS of $0.20 beats by $0.02. Revenue of $40.3M (+21.8% Y/Y) in-line. Shares +0.4% AH. (PR) Comment! [Earnings, Healthcare]
Wednesday, August 8, 2012, 12:10 AM Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX Comment! [Earnings]
Tuesday, August 7, 2012, 5:35 PM Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX 2 Comments [Earnings]
Wednesday, July 11, 2012, 9:48 AM SA author The GeoTeam argues that SciClone (SCLN) faces risks that should see it trade at $2.65-$3.80. These include: the failure of the firm's Zadaxin drug, its lead product, in multiple Phase III studies for various uses; probable price reductions in China, SciClone's main source of revenue; and an SEC investigation into bribery in the country. Shares -5.4% to $6.50. Comment! [Healthcare, On the Move]
Wednesday, May 9, 2012, 5:10 PM SciClone Pharmaceuticals (SCLN): Q1 EPS of $0.15 beats by $0.04. Revenue of $39.2M (+81% Y/Y) beats by $2M. Shares +1.7% AH. (PR) Comment! [Earnings, Healthcare]
Monday, April 9, 2012, 9:05 AM Premarket gainers: AOL +35%. GOLD +7%. SCLN +4%.
Losers: MOH -22%. HOGS -11%. OPTR -5%. RDN -4%. AVP -4%. ALU -4%. DRYS -3%. S -3%. X -3%. Comment! [On the Move]

Kapitall
Income Idea: 2 Undervalued Drug Makers With Rising Gross Profit Margins $SCLN $WCRX http://seekingalpha.com/a/ui5n
May 10, 7:47 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

JML123
Why the jump in $SCLN today?
Jan 28, 3:50 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Zachary Schenk
Interesting drop by $SCLN today
12/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
11 Stocks Breaking Down http://bit.ly/Sy5D2O BSRR HL KIRK OESX PLG SCLN SURG TDW TEAR UHS WIT
11/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Low-Debt Healthcare Stocks With Hefty Earnings Trends http://bit.ly/Tjjpsm $MD $SCLN $SNN $YDNT @ZetaKap
9/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joe Springer
#biotech #pharma #stocks $VNDA $LLY $PPHM $GHDX $SCLN $AMRN $CRTX $NVS Vanda looks like a buy here: http://seekingalpha.com/a/h3pb
8/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Profitable Small-Cap Healthcare Stocks With Cash On Hand http://bit.ly/OrPoFo $AMSG $ATRI $HITK $KH $SCLN $VIVO $VPHM @ZetaKap
8/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
Four Stocks Hitting New Highs In A Weak Tape http://seekingalpha.com/a/e1xn CAMP SCLN SYPR INOD
6/16/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Roy Manning III
SCLN is up over 5% today. Check out my article.
4/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Day Trading Radar and Market Commentary for Friday $GLUU $AKRX $ELGX $SCLN http://bit.ly/nautH1/
7/15/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

SCLN SciClone Pharmaceuticals, Inc.

SCLN

SciClone Pharmaceuticals, Inc.